Intelligence · Clinical Pipeline
Infectious disease · Phase III
Infectious disease programs at Phase III — ClinicalTrials.gov pipeline intelligence.
- Programs
- 302
Quick answer
Infectious disease Phase III programs: NovaPharmaNews indexes 302 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- United Therapeutics Europe 22 programs
- GSK Glaxo Smith 20 programs
- BRIGHT MINDS BIOSCIENCES 18 programs
- Chinese Academy of 13 programs
- Takeda 12 programs
- Sinovac Research and 11 programs
- Gilead Sciences Ireland 10 programs
- PARItec 10 programs
- Gilead Sciences 9 programs
- Pfizer 8 programs
- Vir Biotechnology 7 programs
- George Institute for 6 programs
-
Motivational interviewing
BRIGHT MINDS BIOSCIENCES INC.
HIV
1 trial -
NIRMATRELVIR, NIRMATRELVIR, Ritonavir, nirmatrelvir / ritonavir
Pfizer Australia Pty Ltd
SARS-CoV-2 Infection
1 trial -
Nacubactam, Imipenem/Cilastatin Kabi 500 mg/500 mg Pulver zur Herstellung einer Infusionslösung, Cefepim PANPHARMA 2 g Pulver zur Herstellung einer Injektions- bzw. Infusionslösung, AZACTAM 1 g, poudre et solution pour usage parentéral
Lacuna Pharma Pty Ltd
Complicated urinary tract infection (cUTI) and acute uncomplicated pyelonephritis (AP)
1 trial -
Nanocovax
Biotech Pharmaceutical Co.,
SARS-CoV-2 Infection
1 trial -
Niclosamide
United Therapeutics Europe Ltd
Covid19
1 trial -
Nimenrix
GlaxoSmithKline
Infections, Meningococcal
1 trial -
Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Nimenrix powder and s
Sanofi Pasteur
Healthy volunteers (Meningococcal infection)
1 trial -
Omicron COVID-19 Vaccine (Vero Cell), Inactivated
Xiyuan Hospital of China Academy of Chinese Medical Sciences
COVID-19
2 trials -
On-site bundled rapid HIV/HCV testing
BRIGHT MINDS BIOSCIENCES INC.
Substance-related Disorders
1 trial -
One4All
BRIGHT MINDS BIOSCIENCES INC.
HIV
1 trial -
Opaganib
RedHill Biopharma
COVID-19
2 trials -
PCV21
Sanofi Pasteur
Pneumococcal Infections
1 trial -
PEG-Interferon a-2b + Ribavirin
Universal Integrated
Chronic Hepatitis C Infection in HIV-Infected Persons
1 trial -
PEG-interferon-Alfa-2A
Hospital Authority, Hong Kong
Chronic Hepatitis B
1 trial -
PF-07321332
Pfizer
COVID-19
2 trials -
PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , NEGABAN 2 g, poudre pour solution injectable/pour perfusion, MEROPENEM ARROW 1 g, poudre pour solution injectable / pour perfusion
Pari Pharma GmbH
patients hospitalized in ICU with ESBL-producing Enterobacteriaceae severe infection
1 trial -
PREVYMIS 240 mg film-coated tablets, Placebo of prevymis 240 mg tablets (letermovir), VALGANCICLOVIR
Pari Pharma GmbH
CytoMegaloVirus infections, Kidney transplant
1 trial -
PRO 2000/5
United Therapeutics Europe Ltd
HIV Infections
1 trial -
PTM 300 mg tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, PTM 75/50 mg FDC tablets, PTM 50/200/25 mg FDC tablets, Sunlenca 300 mg film-coated tablets, BICTEGRAVIR 75 MG/LENACAPAVIR 50 MG FDC TABLETS
Gilead Sciences Pty Limited
HIV-1 infection
1 trial -
Paeoniflorin + phosphatidylcholine or silymarin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatitis, Autoimmune
1 trial -
Panzyga 100 mg/ml Infusionslösung, Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung
Maze Therapeutics
Prevention of a Major infection in patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions receiving treatment with B-cell depletion therapy.
1 trial -
Part A: Upamostat 200 mg
RedHill Biopharma
Covid19
1 trial -
Peer HIV Education Program
BRIGHT MINDS BIOSCIENCES INC.
HIV Infections
1 trial -
Peer Mentoring Intervention for HCV-Infected IDUs
BRIGHT MINDS BIOSCIENCES INC.
Hepatitis C
1 trial -
Peg interferon alpha-2b
Universal Integrated
Hepatitis C
1 trial -
PegIntron (peginterferon alfa-2b)
Universal Integrated
Hepatitis C, Chronic
1 trial -
Pegylated Interferon Alfa 2a
Vertex Pharmaceuticals (Australia) Pty.
Infection
1 trial -
Pegylated Interferon Alfa 2a
Vertex Pharmaceuticals (Australia) Pty.
Hepatitis C
1 trial -
Permethrin, InfectoScab® 5 % Crème
Alphapharm Pty Ltd
Scabies
1 trial -
Pioglitazone
Takeda
HIV-Associated Lipodystrophy Syndrome
1 trial -
Placebo
GlaxoSmithKline
Infections, Papillomavirus
1 trial -
Placebo
Tobira Therapeutics
Nonalcoholic Steatohepatitis
1 trial -
Placebo 0 mg/1 mL Solution for infusion/injection, VAY736
Novartis Pharmaceuticals
Autoimmune hepatitis
1 trial -
Placebo capsules for Doxycycline 200 mg (Empty Hpmc capsule, vcaps plus, swedish orange filled with microcrystalline cellulose), Doxycycline EG 100 mg tabletten
The George Institute
bacterial sexually transmitted infections
1 trial -
Placebo de fasturtec, Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion.
Pari Pharma GmbH
Patients hospitalised in intensive care, diagnosed with sepsis less than 48 hours ago, uric acid level ≥200µmol/L, adults, negative G6PD deficiency
1 trial -
Placebo for Bepirovirsen Solution for Injection 150 mg/mL
GlaxoSmithKline
Hepatitis B, Chronic
1 trial -
Placebo for Bepirovirsen Solution for Injection 150 mg/mL
GlaxoSmithKline
Hepatitis B, Chronic
1 trial -
Placebo is a solution for infusion of human albumin 1%, is an albumin preparation manufactured by dilution from the drug product of Albiomin 20%, it will be administrated via intravenous infusion., Trimodulin (human IgM, IgA, IgG solution)
Biotest Pharma GmbH
Non-severe community-acquired pneumonia (CAP) or moderate or severe Coronavirus Disease 2019 (COVID-19)
1 trial -
Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg
Amneal Pharma Europe Ltd
Uncomplicated Urinary Tract Infections
1 trial -
Placebo to Ibuzatrelvir film-coated tablet, PF-07817883 Tablet
Pfizer Australia Pty Ltd
Covid-19 at high risk of progression to severe illness.
1 trial -
Placebo to Remdesivir - Saline, Remdesivir, PF-07817883 Tablet, Placebo to Ibuzatrelvir
Pfizer Australia Pty Ltd
Coronavirus Disease 2019 (COVID-19)
1 trial -
Placebo to doravirine/ islatravir, MK-8591A, Placebo to bictegravir/ emtricitabine/ tenofovir alafenamide, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets
Merck Sharp and Dohme
HIV-1 Infection
1 trial -
Prevnar 13™
Merck KGaA, Darmstadt, Germany
Pneumococcal Infections
1 trial -
RESPIRATORY SYNCYTIAL VIRUS VACCINES
The George Institute
RSV infection
1 trial -
RHB-105
RedHill Biopharma
Helicobacter Pylori Infection
1 trial -
RHB-204
RedHill Biopharma
Pulmonary Mycobacterium Avium Complex Infection
1 trial -
RIFADINE 300 mg, gélule, ANSATIPINE 150 mg, gélule
Tour Hekla
Adult with an staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy)
1 trial -
RO7496998
Atea Pharmaceuticals
COVID-19
1 trial
Frequently asked questions
How many infectious disease Phase III programs exist?
302 programs match both the therapeutic area and stage filters in our published index.
Data attribution: Data sources · All pipeline programs